Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Guendalina Froechlich"'
Autor:
Guendalina Froechlich, Arianna Finizio, Alessandra Napolano, Sara Amiranda, Arianna De Chiara, Pasqualina Pagano, Massimo Mallardo, Guido Leoni, Nicola Zambrano, Emanuele Sasso
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-16 (2023)
Abstract Different innate immune pathways converge to Stimulator of interferon genes (STING) and trigger type I interferon responses after recognition of abnormal nucleic acids in the cells. This non-redundant function renders STING a major player in
Externí odkaz:
https://doaj.org/article/92093d7dd82e4ff1bfccb46468f53564
Autor:
Maria De Lucia, Gabriella Cotugno, Veronica Bignone, Irene Garzia, Linda Nocchi, Francesca Langone, Biljana Petrovic, Emanuele Sasso, Simona Pepe, Guendalina Froechlich, Chiara Gentile, Nicola Zambrano, Gabriella Campadelli-Fiume, Alfredo Nicosia, Elisa Scarselli, Anna Morena D’Alise
Publikováno v:
Molecular Therapy: Oncolytics, Vol 19, Iss , Pp 253-264 (2020)
Oncolytic viruses (OVs) are novel anti-tumor agents with the ability to selectively infect and kill tumor cells while sparing normal tissue. Beyond tumor cytolysis, OVs are capable of priming an anti-tumor immune response via lysis and cross-presenta
Externí odkaz:
https://doaj.org/article/b42887904459445c8ca4a40719963797
Autor:
Rosa Rapuano Lembo, Lorenzo Manna, Guendalina Froechlich, Emanuele Sasso, Margherita Passariello, Claudia De Lorenzo
Publikováno v:
Cancers, Vol 14, Iss 21, p 5289 (2022)
Antibody-based cancer immunotherapy includes monoclonals against immune checkpoints (ICs), to modulate specific T cell responses against cancer. NK cells are a newly emerging target for immune checkpoint receptor inhibition in cancer immunotherapy, a
Externí odkaz:
https://doaj.org/article/d63d1a9183af49d1a1ca9dda47ce3328
Autor:
Margherita Passariello, Anna Morena D’Alise, Annachiara Esposito, Cinzia Vetrei, Guendalina Froechlich, Elisa Scarselli, Alfredo Nicosia, Claudia De Lorenzo
Publikováno v:
Scientific Reports, Vol 9, Iss 1, Pp 1-13 (2019)
Abstract The novel antibody-based immunotherapy in oncology exploits the activation of immune system mediated by immunomodulatory antibodies specific for immune checkpoints. Among them, the programmed death ligand-1 (PD-L1) is of particular interest
Externí odkaz:
https://doaj.org/article/d9ecd4a1d8dd4bf3b9fda68c98a561a7
Autor:
Nicola Zambrano, Guendalina Froechlich, Dejan Lazarevic, Margherita Passariello, Alfredo Nicosia, Claudia De Lorenzo, Marco J. Morelli, Emanuele Sasso
Publikováno v:
Cancers, Vol 14, Iss 5, p 1325 (2022)
Monoclonal antibodies are among the most powerful therapeutics in modern medicine. Since the approval of the first therapeutic antibody in 1986, monoclonal antibodies keep holding great expectations for application in a range of clinical indications,
Externí odkaz:
https://doaj.org/article/968da938429342599120ec4f2159ba58
Autor:
Chiara Gentile, Arianna Finizio, Guendalina Froechlich, Anna Morena D’Alise, Gabriella Cotugno, Sara Amiranda, Alfredo Nicosia, Elisa Scarselli, Nicola Zambrano, Emanuele Sasso
Publikováno v:
International Journal of Molecular Sciences, Vol 22, Iss 24, p 13521 (2021)
Background: Oncolytic viruses are immunotherapeutic agents that can be engineered to encode payloads of interest within the tumor microenvironment to enhance therapeutic efficacy. Their therapeutic potential could be limited by many avenues for immun
Externí odkaz:
https://doaj.org/article/c00e014feb9a45c289fc3c5b76b7337f
Autor:
Cinzia Vetrei, Margherita Passariello, Guendalina Froechlich, Rosa Rapuano Lembo, Emanuele Sasso, Nicola Zambrano, Claudia De Lorenzo
Publikováno v:
Cancers, Vol 14, Iss 1, p 121 (2021)
Triple-negative breast cancer (TNBC) is a highly aggressive subtype of breast cancer characterized by a higher mortality rate among breast cancer subtypes. Poly(ADP-ribose) polymerase (PARP) inhibitors are used in clinics to treat a subgroup of TNBC
Externí odkaz:
https://doaj.org/article/7942de754de74f4fae30652d05c8b8c4
Autor:
Cinzia Vetrei, Margherita Passariello, Guendalina Froechlich, Rosa Rapuano Lembo, Nicola Zambrano, Claudia De Lorenzo
Publikováno v:
Cancers, Vol 13, Iss 12, p 2858 (2021)
Antibodies targeting Immune Checkpoints (IC) on tumor infiltrating lymphocytes improve immune responses against cancer. Recently, the expression of some ICs has also been reported on cancer cells. We used the clinically validated Ipilimumab and Nivol
Externí odkaz:
https://doaj.org/article/529ad3c1339e4a5ea918b056fe3e9ff4
Autor:
Guendalina Froechlich, Chiara Gentile, Luigia Infante, Carmen Caiazza, Pasqualina Pagano, Sarah Scatigna, Gabriella Cotugno, Anna Morena D’Alise, Armin Lahm, Elisa Scarselli, Alfredo Nicosia, Massimo Mallardo, Emanuele Sasso, Nicola Zambrano
Publikováno v:
International Journal of Molecular Sciences, Vol 22, Iss 2, p 477 (2021)
Background: HER2-based retargeted viruses are in advanced phases of preclinical development of breast cancer models. Mesothelin (MSLN) is a cell-surface tumor antigen expressed in different subtypes of breast and non-breast cancer. Its recent identif
Externí odkaz:
https://doaj.org/article/9f921a9fca6b41f78ff688e821cd765f
Autor:
Guendalina Froechlich, Carmen Caiazza, Chiara Gentile, Anna Morena D’Alise, Maria De Lucia, Francesca Langone, Guido Leoni, Gabriella Cotugno, Vittorio Scisciola, Alfredo Nicosia, Elisa Scarselli, Massimo Mallardo, Emanuele Sasso, Nicola Zambrano
Publikováno v:
Cancers, Vol 12, Iss 11, p 3407 (2020)
The dichotomic contribution of cancer cell lysis and tumor immunogenicity is considered essential for effective oncovirotherapy, suggesting that the innate antiviral immune response is a hurdle for efficacy of oncolytic viruses. However, emerging evi
Externí odkaz:
https://doaj.org/article/f6a854c5bfbb4a4cafbbc18aecbb4d58